Clinical activity of eribulin in advanced desmoplastic small round-cell tumorEmambux, Sheika; Kind, Micheleb; Le Loarer, Francoisc; Toulmonde, Mauda; Stoeckle, Eberhardd; Italiano, AntoineaAnti-Cancer Drugs: October 2017 - Volume 28 - Issue 9 - p 1053–1055 doi: 10.1097/CAD.0000000000000536 CASE REPORTS Buy Abstract Author InformationAuthors Article MetricsMetrics Desmoplastic small round-cell tumor is a rare but highly aggressive tumor occurring mainly in adolescents and young adults. Prolonged progression-free survival has been documented in patients who have undergone aggressive multimodality therapy – that is, multiagent intensive chemotherapy, debulking surgery, and radiation therapy. Eribulin is a microtubule-dynamics inhibitor, and it has recently been shown to be active in liposarcomas. In preclinical models, eribulin activities have also been shown to occur in Ewing’s sarcoma cell lines, rhabdomyosarcomas and osteosarcomas. In this study, we report three cases of male patients suffering from desmoplastic small round-cell tumor and the clinical response to eribulin in two of them. Departments of aMedical Oncology bRadiology cPathology dSurgery, Institut Bergonie, Bordeaux, France Correspondence to Antoine Italiano, MD, PhD, Department of Medical Oncology, Institut Bergonie, 229 Cours de l’Argonne, 33076 Bordeaux, France Tel: +33 547 306 088; fax: +33 547 306 083; e-mail: firstname.lastname@example.org Received March 24, 2017 Accepted June 6, 2017 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.